CA3212210A1 - Compounds targeting fibroblast-activation protein and methods of use thereof - Google Patents
Compounds targeting fibroblast-activation protein and methods of use thereof Download PDFInfo
- Publication number
- CA3212210A1 CA3212210A1 CA3212210A CA3212210A CA3212210A1 CA 3212210 A1 CA3212210 A1 CA 3212210A1 CA 3212210 A CA3212210 A CA 3212210A CA 3212210 A CA3212210 A CA 3212210A CA 3212210 A1 CA3212210 A1 CA 3212210A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- imaging
- isotope
- radio
- radiotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163200592P | 2021-03-16 | 2021-03-16 | |
| US202163161835P | 2021-03-16 | 2021-03-16 | |
| US202163200593P | 2021-03-16 | 2021-03-16 | |
| US63/161,835 | 2021-03-16 | ||
| US63/200,593 | 2021-03-16 | ||
| US63/200,592 | 2021-03-16 | ||
| US202163165563P | 2021-03-24 | 2021-03-24 | |
| US202163165583P | 2021-03-24 | 2021-03-24 | |
| US202163165550P | 2021-03-24 | 2021-03-24 | |
| US63/165,563 | 2021-03-24 | ||
| US63/165,550 | 2021-03-24 | ||
| US63/165,583 | 2021-03-24 | ||
| PCT/US2022/020084 WO2022197567A1 (en) | 2021-03-16 | 2022-03-12 | Compounds targeting fibroblast-activation protein and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3212210A1 true CA3212210A1 (en) | 2022-09-22 |
Family
ID=83320754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3212210A Pending CA3212210A1 (en) | 2021-03-16 | 2022-03-12 | Compounds targeting fibroblast-activation protein and methods of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240238458A1 (https=) |
| EP (1) | EP4308110A4 (https=) |
| JP (1) | JP2024510267A (https=) |
| CA (1) | CA3212210A1 (https=) |
| TW (1) | TW202300143A (https=) |
| WO (1) | WO2022197567A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI879182B (zh) * | 2023-10-26 | 2025-04-01 | 國家原子能科技研究院 | 白蛋白雙重結合功能之纖維母細胞活化蛋白化合物或其鹽 |
| WO2025155818A1 (en) * | 2024-01-19 | 2025-07-24 | Purdue Research Foundation | Fibroblast activation protein-targeted radioligands with pharmacokinetic modulators |
| WO2025171343A1 (en) * | 2024-02-08 | 2025-08-14 | Immunome, Inc. | Compounds targeting fibroblast-activation protein and methods of use thereof |
| CN118593732B (zh) * | 2024-06-27 | 2025-03-11 | 华中科技大学同济医学院附属同济医院 | 一种心肌炎核素分子探针及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1943257A2 (en) * | 2005-05-19 | 2008-07-16 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| US8071787B2 (en) * | 2009-03-13 | 2011-12-06 | National Health Research Institutes | Pyrrolidine compounds |
| JP6744826B2 (ja) * | 2014-06-13 | 2020-08-19 | バック バイオサイエンシーズ, エルエルシーBach BioSciences, LLC | Ｆａｐ活性化治療剤及びそれに関連する使用 |
| CN116474108A (zh) * | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| JP7094591B2 (ja) * | 2018-03-30 | 2022-07-04 | フューチャーケム カンパニー リミテッド | 前立腺がんを診断および処置するためのｐｓｍａ標的放射性医薬品 |
| US11426472B2 (en) * | 2018-10-17 | 2022-08-30 | Purdue Research Foundation | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis |
| EP3946320A4 (en) * | 2019-04-03 | 2022-12-28 | Tva (Abc), Llc | CONJUGATES RELATED TO HSP90 AND FORMULATIONS THEREOF |
| WO2021016392A1 (en) * | 2019-07-22 | 2021-01-28 | Purdue Research Foundation | Multivalent fibroblast-targeted agents and methods of use |
-
2022
- 2022-03-12 US US18/550,964 patent/US20240238458A1/en active Pending
- 2022-03-12 EP EP22771974.7A patent/EP4308110A4/en active Pending
- 2022-03-12 WO PCT/US2022/020084 patent/WO2022197567A1/en not_active Ceased
- 2022-03-12 JP JP2023556985A patent/JP2024510267A/ja active Pending
- 2022-03-12 CA CA3212210A patent/CA3212210A1/en active Pending
- 2022-03-15 TW TW111109356A patent/TW202300143A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240238458A1 (en) | 2024-07-18 |
| EP4308110A4 (en) | 2025-06-18 |
| JP2024510267A (ja) | 2024-03-06 |
| WO2022197567A1 (en) | 2022-09-22 |
| EP4308110A1 (en) | 2024-01-24 |
| TW202300143A (zh) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3212210A1 (en) | Compounds targeting fibroblast-activation protein and methods of use thereof | |
| ES3044433T3 (en) | Compositions for use in a method of treating an estrogen receptor associated cancer | |
| AU2020348781B2 (en) | Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases | |
| TWI870398B (zh) | Ｈｓｐ９０靶定性共軛體類及其調製劑 | |
| CN110386919B (zh) | 核转运调节剂及其用途 | |
| JP7487110B2 (ja) | Ｈｓｐ９０標的化コンジュゲート及びその製剤 | |
| CA3147895A1 (en) | Multivalent fibroblast-targeted agents and methods of use | |
| WO2021068898A1 (zh) | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 | |
| EA024391B1 (ru) | Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1 | |
| TW202222311A (zh) | 結合熱休克蛋白９０（ｈｓｐ９０）之共軛體和彼之調製劑 | |
| US11767298B2 (en) | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase | |
| WO2021083328A1 (zh) | 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途 | |
| CA3205844A1 (en) | Ligands and their use | |
| KR20230035311A (ko) | Nek7 키나제의 억제제 | |
| CN110143956A (zh) | 他克林-吡啶并噻吩类化合物及其制备方法与用途 | |
| CN102603630A (zh) | 邻氨基苯甲酸磺酰化衍生物及其制备方法和应用 | |
| CN117279629A (zh) | 烯胺n-氧化物：合成及在缺氧响应性前药和显像剂中的应用 | |
| AU2023285721B2 (en) | Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein | |
| JP2022514685A (ja) | ペンタミジンの類似体及びその使用 | |
| CN117460507A (zh) | 靶向成纤维细胞激活蛋白的化合物及其使用方法 | |
| US20150284371A1 (en) | Heterocycle-bisamide inhibitors of scavenger receptor bi | |
| CN120569387A (zh) | Par2的小分子调节剂及其用途 | |
| WO2025264849A1 (en) | Glp-1 agonists and methods of use | |
| EA045754B1 (ru) | Аналоги пентамидина и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260306 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260306 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260312 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260312 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260312 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260324 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260324 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260324 |